Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
强化屏障:了解细胞包膜修饰如何促进鲍曼不动杆菌内在的抗菌药物耐受性和耐药性
基本信息
- 批准号:10437019
- 负责人:
- 金额:$ 36.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:Acinetobacter baumanniiAddressAntibiotic ResistanceAntimicrobial ResistanceBacteremiaCell WallColistinDefectDevelopmentEnzymesFosteringGram-Negative BacteriaHospitalsHumanInfectionIntrinsic factorKnowledgeLeadLinkMembraneMissionModelingModificationMulti-Drug ResistanceNosocomial InfectionsPeptidoglycanPharmaceutical PreparationsPhenotypePublic HealthRegimenResistanceResortStressSuperbugTherapeuticTreatment ProtocolsUnited States National Institutes of HealthUrinary tractWorkWound Infectionantimicrobialantimicrobial tolerancecarbapenem resistancecell envelopecolistin resistancecombatcombinatorialdesignextensive drug resistancehuman diseaseimprovedmembrane assemblypathogenresistance generesistance mechanismresponse
项目摘要
Project Summary/Abstract
Emergence of multidrug and extensively drug resistant Gram-negative bacteria is a growing problem that threatens
established antimicrobial treatment protocols. Acinetobacter baumannii is an emerging critical threat pathogen
notorious for its ability to rapidly develop intrinsic multidrug resistance. A. baumannii causes hospital-acquired
infections, which manifest as bacteremia, urinary tract and wound infections. In the US, an estimated 60% of
hospital-acquired A. baumannii infections were multidrug resistant, often including carbapenem resistance, which
leaves colistin as the “last-resort” treatment option. However, colistin resistance has also emerged. There is an
urgent need to understand intrinsic mechanisms that promote antibiotic resistance phenotypes in A. baumannii to
guide alternative antimicrobial strategies. Our preliminary work has identified factors that promote acquisition of
multidrug resistance, including carbapenem and colistin resistance, in A. baumannii. Specifically, links between the
outer membrane and peptidoglycan layers of the cell envelope are key for the resistance phenotypes, where one
layer compensates for defects in the other. While enzymes that assemble the outer membrane and cell wall are
largely known, A. baumannii encodes unique regulatory mechanisms to control their activity in response to stress.
In this proposal, we will address three important questions to understand intrinsic antibiotic resistance in A.
baumannii. The questions will explore the relationship between peptidoglycan and outer membrane assembly, which
is poorly understood in Gram-negative bacteria. Findings from this work will enable us to build a model of intrinsic
factors in A. baumannii that lead to multidrug resistance and will help in the design of combinatorial drug regimens
that target both essential layers, thus precluding resistance; consequently, our findings support the National
Institute of Health mission, which aims to foster fundamental discoveries to reduce human disease.
项目总结/摘要
多重耐药和广泛耐药革兰氏阴性菌的出现是一个日益严重的问题,威胁着
制定了抗菌治疗方案。鲍曼不动杆菌是一种新出现的严重威胁病原体
它因其迅速发展内在多药耐药性的能力而臭名昭著。A.鲍曼不动杆菌引起医院获得性
感染,表现为菌血症、尿路和伤口感染。在美国,估计有60%的
医院获得性A.鲍曼不动杆菌感染具有多药耐药性,通常包括碳青霉烯类耐药,
使得粘菌素成为“最后的”治疗选择。然而,也出现了粘菌素耐药性。有一个
迫切需要了解的内在机制,促进抗生素耐药表型在A。鲍曼不动杆菌对
指导替代抗菌策略。我们的初步工作已经确定了促进收购的因素,
多药耐药,包括碳青霉烯类和粘菌素耐药。鲍曼不动杆菌。具体而言,
细胞包膜的外膜和肽聚糖层是耐药表型的关键,其中一个
一层弥补另一层的缺陷。而组装外膜和细胞壁的酶则是
众所周知,A。鲍曼不动杆菌编码独特的调节机制以控制它们响应压力的活性。
在这个建议中,我们将解决三个重要的问题,以了解内在的抗生素耐药性在A。
鲍曼不动杆菌。这些问题将探讨肽聚糖和外膜组装之间的关系,
在革兰氏阴性菌中知之甚少。这项工作的结果将使我们能够建立一个内在的模型,
因素在A.鲍曼不动杆菌,导致多药耐药性,并将有助于设计组合药物方案
针对两个基本层,从而排除阻力;因此,我们的研究结果支持国家
卫生研究所的使命,旨在促进基本发现,以减少人类疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Michael Boll其他文献
Joseph Michael Boll的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Michael Boll', 18)}}的其他基金
Mechanistic basis of how LD-transpeptidases protect against outer membrane defects
LD-转肽酶如何防止外膜缺陷的机制基础
- 批准号:
10586069 - 财政年份:2022
- 资助金额:
$ 36.66万 - 项目类别:
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
强化屏障:了解细胞包膜修饰如何促进鲍曼不动杆菌内在的抗菌药物耐受性和耐药性
- 批准号:
10605318 - 财政年份:2021
- 资助金额:
$ 36.66万 - 项目类别:
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
强化屏障:了解细胞包膜修饰如何促进鲍曼不动杆菌内在的抗菌药物耐受性和耐药性
- 批准号:
10880873 - 财政年份:2021
- 资助金额:
$ 36.66万 - 项目类别:
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
强化屏障:了解细胞包膜修饰如何促进鲍曼不动杆菌内在的抗菌药物耐受性和耐药性
- 批准号:
10276854 - 财政年份:2021
- 资助金额:
$ 36.66万 - 项目类别:
Solving a Multidrug Resistance Puzzle: Complete Loss of Lipooligosaccharide
解决多药耐药性难题:脂寡糖完全丧失
- 批准号:
9808273 - 财政年份:2019
- 资助金额:
$ 36.66万 - 项目类别:
Solving a Novel Multidrug Resistance Puzzle: Complete Loss of Lipooligosaccharide
解决新的多药耐药性难题:脂寡糖的完全丧失
- 批准号:
8833481 - 财政年份:2015
- 资助金额:
$ 36.66万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.66万 - 项目类别:
Research Grant